EDITORIAL COMMENT   Free access

Minerva Urology and Nephrology 2021 October;73(5):674-6

DOI: 10.23736/S2724-6051.21.04762-5

Copyright © 2021 EDIZIONI MINERVA MEDICA

lingua: Inglese

Is there enough evidence available nowadays to suggest a paradigmatic shift in treatment of MIBC with perioperative systemic therapy administration?

Francesco DEL GIUDICE ^{1, 2} ✉, David D’ANDREA ³, Andrea MARI ⁴, Francesco SORIA ⁵, Wojciech KRAJEWSKI ⁶, Marco MOSCHINI ⁷ on behalf of the YAU Urothelial Working Group

¹ Department of Maternal-Infant and Urological Sciences, Policlinico Umberto I Hospital, Sapienza University of Rome, Rome, Italy; ² Department of Urology, Stanford Medical Center, Stanford, CA, USA; ³ Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; ⁴ Unit of Oncologic Minimally-Invasive Urology and Andrology, Department of Experimental and Clinical Medicine, Careggi University Hospital, University of Florence, Florence, Italy; ⁵ Division of Urology, Department of Surgical Sciences and Urology, Molinette Hospital, Città della Salute e della Scienza, Turin, Italy; ⁶ Department of Minimally Invasive and Robotic Urology, Wroclaw Medical University, University Center of Excellence in Urology, Wroclaw, Poland; ⁷ Division of Experimental Oncology, Department of Urology, Urological Research Institute, Vita-Salute San Raffaele University, Milan, Italy